Insulin oral - BioSante Pharmaceuticals

Drug Profile

Insulin oral - BioSante Pharmaceuticals

Alternative Names: BioOral Insulin

Latest Information Update: 28 Jul 2008

Price : $50

At a glance

  • Originator BioSante Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 30 Apr 2008 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
  • 03 Jun 2004 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
  • 11 Sep 2003 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top